natgillin/translations-raw huggingface dataset:
Composition as claimed in any one of the claims from 11 to 14, characterised in that it comprises 300-1000 mg of gamma-linolenic acid. 
Sastav prema bilo kojem od patentnih zahtjeva od 11 do 14, naznačen time, da sadrži 300 do 1000 mg gama-linolenske kiseline.
Composition as claimed in claim 9, characterised in that said other active ingredient is an ACE inhibitor. 
Sastav prema patentnom zahtjevu 9, naznačen time, da navedena druga aktivna tvar jest ACE inhibitor.
and R7 are each independently selected from the group consisting of H, C1-6alkyl, hydroxy-C2-6alkyl-; 
svakog od R6 i R7 neovisno se bira iz skupine koju čine H, C1-6alkil, hidroksi-C2-6alkil-;
m represents an integer 1-4; and n represents an integer 2-4. 
m predstavlja cijeli broj 1-4; i n predstavlja cijeli broj 2-4.
A compound as claimed in claim 6, wherein R1 represents R20 or NR10R20 and R20 is a substituted or unsubstituted carbocyclyl, heterocyclyl, aryl or heteroaryl group; 
Spoj u skladu s patentnim zahtjevom 6, naznačen time što R1 predstavlja R20 ili NR10R20, a R20 je supstituirana ili nesupstituirana karbociklilna, heterociklilna, arilna ili heteroarilna skupina;
or R1 represents C(O)R20 and R20 is an aryl or heteroaryl group, which may be unsubstituted or substituted as defined in claim 1, or a heterocyclyl group. 
predstavlja C(O)R20, a R20 je arilna ili heteroarilna skupina, koja može biti nesupstituirana ili supstituirana kao što je definirano u patentnom zahtjevu 1, ili heterociklilna skupina.
A compound as claimed in any one of claims 1 to 17 for use in medicine, particularly in the treatment or prevention of diseases and conditions mediated by the activity of cyclin dependent kinases, especially CDK9. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što je namijenjen upotrebi u medicinskom liječenju, osobito u liječenju ili sprječavanju bolesti i stanja uzrokovanih aktivnošću o ciklinu ovisnih kinaza, a osobito CDK9.
A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 17 for use as active ingredient together with a pharmaceutically acceptable excipient or diluent. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 17, namijenjen upotrebi kao aktivni sastojak, uz farmaceutski prihvatljivu pomoćnu tvar ili razrjeđivač.
reacting a compound of formula A wherein A, B, R1, Ra and R2 are as defined in general formula (I) and X is a suitable substituent for a cross coupling reaction, or a protected derivative thereof with a compound of formula B wherein R3 and x are as defined in general formula (I) and Y is a suitable substituent for a cross coupling reaction, or a protected derivative thereof; 
reakciji spoja formule A [image] gdje su A, B, R1, Ra i R2 definirani kao za opću formulu (I), a X je supstituent pogodan za reakciju ukrižene kondenzacije, ili njegovog zaštićenog derivata sa spojem formule B [image] gdje su R3 i x definirani kao za opću formulu (I), a Y je supstituent pogodan za reakciju ukrižene kondenzacije, ili njegov zaštićeni derivat;
wherein X and Y represent suitable substituents for a cross-coupling reaction and are chosen to react with one another; or 
gdje X i Y predstavljaju supstituente pogodne za reakciju ukrižene kondenzacije, tako odabrane da mogu međusobno reagirati; ili
reacting a compound of formula E or a protected derivative thereof wherein R1 is as defined for general formula (I) and L4 represents a suitable leaving group; 
reakciji spoja formule E [image] ili njegovog zaštićenog derivata gdje je R1 definiran kao za opću formulu (I), a L4 predstavlja pogodnu izlaznu skupinu;
preparing a compound of formula (I), in which R1 is a moiety which connects to the main carbonyl of formula (I) via a nitrogen atom by a process comprising reaction of the corresponding amine or a protected derivative thereof with a compound of formula G wherein Ra, R2, R3, x, A and B are as defined for general formula (I) and L2 represents a suitable leaving group; 
dobivanju spoja formule (I), gdje je R1 ostatak koji se veže na glavni karbonil u formuli (I) preko atoma dušika, postupkom koji se sastoji u reakciji odgovarajućeg amina, ili njegovog zaštićenog derivata sa spojem formule G [image] gdje su Ra, R2, R3, x, A i B definirani kao za opću formulu (I), a L2 predstavlja pogodnu izlaznu skupinu;
or a protected derivative thereof; 
ili njegovim zaštićenim derivatom;
reacting a compound of formula F as defined above or a protected derivative thereof with a compound of formula J wherein R1 is as defined for general formula (I); in the presence of a suitable coupling agent; or 
reakciji spoja formule F, definirane kao gore, ili njegovog zaštićenog derivata sa spojem formule J [image] gdje je R1 definiran kao za opću formulu (I); u prisutnosti pogodnog kondenzacijskog sredstva; ili
reacting a compound of formula K wherein R2, R3, x, A and B are as defined for general formula (I) and Z represents a suitable substituent for a cross-coupling reaction with a compound of formula L wherein R1 and Ra are as defined for general formula (I); 
reakciji spoja formule K [image] gdje su R2, R3, x, A i B definirani kao za opću formulu (I), a Z predstavlja supstituent pogodan za reakciju ukrižene kondenzacije sa spojem formule L [image] gdje su R1 i Ra definirani kao za opću formulu (I);
under suitable conditions for coupling reaction; or 
u uvjetima pogodnim za reakciju kondenzacije; ili
R20N=C=O or R20-(C1-6alkyl)-N=C=O wherein R20 is as defined for general formula (I), for example R20 represents a heteroaryl group such as pyridine. 
N=C=O ili R20-(C1-6alkil)-N=C=O gdje je R20 definiran kao za opću formulu (I), primjerice R20 predstavlja heteroarilnu skupinu, poput piridina.
The cell of claim 7, wherein the cell is a mammalian cell. 
Stanica prema zahtjevu 7, naznačena time da stanica je stanica sisavca.
providing mammalian cells, wherein the cells comprise a first expression vector and a second expression vector; and 
pružanje stanica sisavca, pri čemu stanice sadrže prvi ekspresijski vektor i drugi ekspresijski vektor; i
A composition comprising the recombinant FSH of claim 1 and a pharmaceutically acceptable carrier or excipient. 
Pripravak naznačen time da sadrži rekombinantni FSH prema zahtjevu 1 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
A recombinant FSH mutant according to claim 1 for use in a method of treating an infertile animal. 
Rekombinantni FSH mutant prema zahtjevu 1 naznačen time da je za upotrebu kod postupka liječenja neplodne životinje.
A recombinant FSH mutant according to claim 1 for use in a method of stimulating folliculogenesis in a mammal. 
Rekombinantni FSH mutant prema zahtjevu 1 naznačen time da je za upotrebu kod postupka stimulacije folikulogeneze kod sisavca.
A recombinant FSH mutant according to claim 1 for use in a method of inducing ovarian hyperstimulation in a mammal. 
Rekombinantni FSH mutant prema zahtjevu 1 naznačen time da je za upotrebu kod postupka induciranja hiperstimulacije jajnika kod sisavca.
Pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
Use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis (IPF), said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of 1400 to 1800 mg/day. Pirfenidone or use according to Claim 1 or 3, wherein (a) said patient is administered pirfenidone at doses of 2200 to 2600 mg/day. 
Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koji je više od 2.5- do 5- puta povećana u usporedbi s gornjom granicom normalnih vrijednosti, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu je davan pirfenidon u dozama od bar 1600 mg/dnevno ili 1602 mg/dnevno.
Pirfenidone for use in treating a patient suffering from renal fibrotic disease, fibrotic vascular disease or scleroderma, said treatment characterized by administering pirfenidone to a patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, said patient having exhibited an abnormal level of alanine transaminase (ALT) and/or aspartate transaminase (AST) that is greater than 2.5-times and less than or equal to 5-times the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
Pirfenidone for use in treating a patient suffering from fibrosis, said patient having exhibited a Grade 2 abnormality in one or both of alanine transaminase (ALT) and aspartate transaminase (AST) that is greater than 2.5-times and less than or equal to 5-times the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
Use of pirfenidone in the manufacture of a medicament for treating a patient suffering from fibrosis, said patient having exhibited a Grade 2 abnormality in one or both of alanine transaminase (ALT) and aspartate transaminase (AST) that is greater than 2.5-times and less than or equal to 5-times the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 –puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 2400 mg/dan ili 2403 mg/dan.
Pirfenidone for use or use according to Claim 1 or 2, wherein (a) said patient is administered pirfenidone at a dose of 2400 mg/day or 2403 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 2, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 2400 mg/dan u tijeku vremenskog perioda.
a cannula (18) attached to the distal end of the body; 
kanilu (18) prikačenu na udaljenom kraju tijela;
a fiber optic cable extending through the hollow body, the fiber optic cable having a fiber optic (16) extending through the cannula (18); and characterized by 
svjetlovodno vlakno koje se proteže kroz šuplje tijelo, a to svjetlovodno vlakno ima optičko vlakno (16) koje se proteže kroz kanilu (18); i
The probe of claim 4, wherein the exposed portion extends beyond the distal end (20) of the cannula (18) a distance of approximately 4.0 millimeters to 6.0 millimeters. 
Sonda prema zahtjevu 4, naznačena time, da se izloženi dio (19) proteže izvan udaljenog kraja (29) kanile (18) na udaljenosti od otprilike 4,0 do 6,0 milimetara.
a detector circuit (DC) electrically connected to the detector coil (C) to detect a change in the electric signal from the detector coil (C). 
krug detektora (DC) koji je električki povezan sa zavojnicom detektora (C) i koji otkriva promjenu električnog signala iz zavojnice detektora (C) kao naznaku vanjskog magnetskog utjecaja mjerača potrošnje.
Meter according to claim 1 or 2, wherein the detector circuit (DC) is arranged to generate an output signal upon detection of a level of the electric signal in a frequency range including at least one frequency component related to the switching operation of the switch mode power supply (PS) exceeding a predetermined threshold. 
Mjerač prema zahtjevu 1, gdje krug detektora (DC) stvara izlazni signal nakon otkrivanja razine električnog signala u rasponu frekvencija koji obuhvaća barem jednu komponentu frekvencije koja je povezana s postupkom električnog uključivanja prekidača izvora energije (PS) i prelazi unaprijed postavljenu graničnu vrijednost.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Device according to Claim 1 or 2, in which the passage (11) is situated outside the area of the panel (3) defined by the columns (12, 13). 
Sustav za prihvat tekućina u skladu s patentnim zahtjevom 1 ili 2, naznačen time što elementi (39) imaju otvore na bočnim stranama (11-13).
A polypeptide comprising (i) a MeCP2 protein or biologically active fragment or a derivative of said protein or fragment, and (ii) a protein transduction domain, wherein the MeCP2 protein is fused to the protein transduction domain, for use in a method of treating a neurodegenerative or a neurodevelopmental disease; wherein said fragment comprises at least 150 amino acids of the MeCP2 protein; and wherein said derivative of said protein or fragment has at least 60 % identity with said MeCP2 protein or fragment thereof; and wherein said fragment or said derivative has at least 60 % of said biological activity, as determined by an in vitro transcription assay described by Nan, X et al., Cell 88: 471-481 (1997). 
Polipeptid, koji sadrži (i) protein MeCP2 ili biološki aktivni fragment ili derivat spomenutog proteina ili fragmenta, i (ii) domenu transdukcije proteina, pri čemu je protein MeCP2 sjedinjen s domenom transdukcije proteina, naznačen time, da se upotrebljava u postupku liječenja neurodegenerativne ili neurorazvijajuće bolesti; pri čemu spomenuti fragment sadrži najmanje 150 amino kiselina proteina MeCP2; i pri čemu spomenuti derivat spomenutog proteina ili fragmenta ima najmanje 60% identičnosti sa spomenutim proteinom MeCP2 ili njegovim fragmentom; i pri čemu spomenuti fragment ili spomenuti derivat ima najmanje 60% spomenute biološke aktivnosti, kako je određeno transkripcijskim ispitivanjem in vitro opisanim prema Nan, X et al., Cell 88: 471-481 (1997).
A polypeptide comprising (i) a MeCP2 protein or biologically active fragment or a derivative of said protein or fragment, and (ii) a protein transduction domain, wherein the MeCP2 protein is fused to the protein transduction domain, for use in a method of treating Rett syndrome; wherein said fragment comprises at least 150 amino acids of the MeCP2 protein; and wherein said derivative of said protein or fragment has at least 60 % identity with said MeCP2 protein or fragment thereof; and wherein said fragment or said derivative has at least 60 % of said biological activity, as determined by an in vitro transcription assay described by Nan, X et al., Cell 88: 471-481 (1997). 
Polipeptid, koji sadrži (i) protein MeCP2 ili biološki aktivni fragment ili derivat spomenutog proteina ili fragmenta, i (ii) domenu transdukcije proteina, pri čemu je protein MeCP2 sjedinjen s domenom transdukcije proteina, naznačen time, da se upotrebljava u postupku liječenja Rett-sindroma; pri čemu spomenuti fragment sadrži najmanje 150 amino kiselina proteina MeCP2; i pri čemu spomenuti derivat spomenutog proteina ili fragmenta ima najmanje 60% identičnosti sa spomenutim proteinom MeCP2 ili njegovim fragmentom; i pri čemu spomenuti fragment ili spomenuti derivat ima najmanje 60% spomenute biološke aktivnosti, kako je određeno transkripcijskim ispitivanjem in vitro opisanim prema Nan, X et al., Cell 88: 471-481 (1997).
The polypeptide of claim 1, wherein the neurodevelopmental disease is due to a reduction of MeCP2 expression or to an impaired function of MeCP2. 
Polipeptid prema zahtjevu 1, naznačen time, da se neurorazvijajuća bolest očekuje uslijed redukcije ekspresije MeCP2 ili uslijed oslabljene funkcije MeCP2.
The use of claim 12, wherein the neurodevelopmental disease is due to a reduction of MeCP2 expression or to an impaired function of MeCP2, particularly wherein the neurodevelopmental disease is Rett syndrome. 
Uporaba prema zahtjevu 12, naznačena time, da je neurorazvijajuća bolest očekivana uslijed redukcije ekspresije MeCP2 ili uslijed oslabljene funkcije MeCP2, posebno kada je neurorazvijajuća bolest Rett-sindrom.
or pharmaceutically acceptable salts, stereoisomers or tautomers thereof. 
ili njegove farmaceutski prihvatljive soli, stereoizomeri ili tautomeri.
and pharmaceutically acceptable salts, tautomers or stereoisomers thereof. 
ili njegove farmaceutski prihvatljive soli, tautomeri ili stereoizomeri.
The use of a compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof for the manufacture of a medicament for the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose) polymerase (PARP). 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koja se mogu poboljšati inhibicijom poli(ADP-riboza) polimeraze (PARP).
The use of a compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof for the manufacture of a medicament for the treatment or prevention of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage. 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju tumora, upalnih bolesti, reperfuzionih povreda, iskemijskih stanja, moždanog udara, bubrežne insuficijencije, kardiovaskularnih bolesti, vaskularnih bolesti različitih od kardiovaskularnih bolesti, dijabetesa, neurodegenerativnih bolesti, retrovirusnih infekcija, oštećenja mrežnice ili starenja kože i oštećenja kože izazvanih UV-zračenjem.
A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof for use in the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose)polymerase (PARP). 
Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, stereoizomer ili tautomer, naznačen time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koje može biti poboljšano inhibicijom poli(ADP-riboza)polimeraze (PARP).
The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any of claims 1 to 16, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal. 
Upotreba spoja formule (I), ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje i/ili profilaksu upalne i/ili alergijske bolesti kod sisavca.
A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in any of claims 1 to 16, for use in the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal. 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što je namijenjen upotrebi u liječenju i/ili profilaksi upalne i/ili alergijske bolesti kod sisavca.
chronic obstructive pulmonary disease (COPD), asthma, rhinitis (such as allergic and/or non-allergic rhinitis), rheumatoid arthritis, atopic dermatitis, psoriasis, urticaria, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, septic shock, inflammatory bowel disease (such as ulcerative colitis and/or Crohn's disease), 
kronične opstruktivne plućne bolesti (COPD), astme, rinitisa (primjerice alergijskog i/ili nealergijskog rinitisa), reumatoidnog artritisa, atopičnog dermatitisa, psorijaze, koprivnjače, alergijskog konjunktivitisa, proljetnog konjunktivitisa, eozinofilnog granuloma, septičnog šoka, upalne bolesti crijeva (primjerice ulceroznog kolitis i/ili Crohnove bolesti), reperfuzijske ozljede miokarda i mozga, kroničnog glomerulonefritisa, endotoksičnog šoka ili sindroma respiratornog distresa kod odraslih, kod sisavca, poput čovjeka.
A pharmaceutical composition comprising a pharmaceutical excipient and an antivirally-effective amount of the compound of any one of claims 1 to 3. 
Farmaceutska smjesa, naznačena time, što sadrži farmaceutski ekscipijent i protiv virusa efikasnu količinu spoja iz bilo kojeg od zahtjeva 1 do 3.
The pharmaceutical composition of claim 4 or 5 or the combination ofany one of claims 6 to 9 for use in medical therapy. 
Farmaceutska smjesa iz zahtjeva 4 ili 5 ili kombinacija iz bilo kojeg od zahtjeva 6 do 9, naznačena time, što se koristi u medicinskoj terapiji.